Vagal blocking improves glycemic control and elevated blood pressure in obese subjects with type 2 diabetes mellitus

S Shikora, J Toouli, M F Herrera, B Kulseng, H Zulewski, R Brancatisano, L Kow, J P Pantoja, G Johnsen, A Brancatisano, K S Tweden, M B Knudson, C J Billington, S Shikora, J Toouli, M F Herrera, B Kulseng, H Zulewski, R Brancatisano, L Kow, J P Pantoja, G Johnsen, A Brancatisano, K S Tweden, M B Knudson, C J Billington

Abstract

Background: An active device that downregulates abdominal vagal signalling has resulted in significant weight loss in feasibility studies.

Objective: To prospectively evaluate the effect of intermittent vagal blocking (VBLOC) on weight loss, glycemic control, and blood pressure (BP) in obese subjects with DM2.

Methods: Twenty-eight subjects were implanted with a VBLOC device (Maestro Rechargeable System) at 5 centers in an open-label study. Effects on weight loss, HbA1c, fasting blood glucose, and BP were evaluated at 1 week to 12 months.

Results: 26 subjects (17 females/9 males, 51 ± 2 years, BMI 37 ± 1 kg/m(2), mean ± SEM) completed 12 months followup. One serious adverse event (pain at implant site) was easily resolved. At 1 week and 12 months, mean excess weight loss percentages (% EWL) were 9 ± 1% and 25 ± 4% (P < 0.0001), and HbA1c declined by 0.3 ± 0.1% and 1.0 ± 0.2% (P = 0.02, baseline 7.8 ± 0.2%). In DM2 subjects with elevated BP (n = 15), mean arterial pressure reduced by 7 ± 3 mmHg and 8 ± 3 mmHg (P = 0.04, baseline 100 ± 2 mmHg) at 1 week and 12 months. All subjects MAP decreased by 3 ± 2 mmHg (baseline 95 ± 2 mmHg) at 12 months.

Conclusions: VBLOC was safe in obese DM2 subjects and associated with meaningful weight loss, early and sustained improvements in HbA1c, and reductions in BP in hypertensive DM2 subjects. This trial is registered with ClinicalTrials.gov NCT00555958.

Figures

Figure 1
Figure 1
(a) Relationship of change in fasting plasma glucose (mg/dL) at 12 months compared to baseline, P < 0.0001, r = −0.85. (b) Relationship of change in HbA1c (%) at 12 months compared to baseline P < 0.0001, r = −0.8.

References

    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053.
    1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. The Lancet. 2011;378(9785):31–40.
    1. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care. 1997;20(11):1744–1766.
    1. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. Journal of the American Medical Association. 1999;282(16):1523–1529.
    1. Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2010;12(3):186–194.
    1. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. The New England Journal of Medicine. 2012;366:1577–1585.
    1. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. The New England Journal of Medicine. 2012;366:1567–1576.
    1. Guyton AC, Hall JE. Textbook of Medical Physiology. 10th edition. St. Louis, Mo, USA: W.B. Saunders Company; 2000.
    1. Pardo JV, Sheikh SA, Schwindt GC, et al. Chronic vagus nerve stimulation for treatment-resistant depression decreases resting ventromedial prefrontal glucose metabolism. NeuroImage. 2008;42(2):879–889.
    1. Kral JG, Paez W, Wolfe BM. Vagal nerve function in obesity: therapeutic implications. World Journal of Surgery. 2009;33(10):1995–2006.
    1. Camilleri M, Toouli J, Herrera MF, Kow L, Pantoja JP, Billington CJ, et al. Selection of electrical algorithms to treat obesity with intermittent vagal block using an implantable medical device. Surgery for Obesity and Related Diseases. 2009;5:224–230.
    1. Camilleri M, Toouli J, Herrera MF, et al. Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device. Surgery. 2008;143(6):723–731.
    1. Tweden KS, Sarr MG, Bierk MD, Camilleri M, Kendrick ML, Knudson MB, et al. Vagal blocking for obesity control (VBLOC): studies of pancreatic and gastric function and safety in a porcine model. Surgery For Obesity and Related Diseases. 2006;2(3):301–302.
    1. Herrera MF, Brancatisano R, Keller U, Kulseng B, Toouli J, Brancatisano A, et al. Intermittent vagal blockade with an implantable device improves glycemic control in obese subjects with type 2 diabetes. Surgery For Obesity and Related Diseases. 2009;5(Supplement)(3):S48–S49.
    1. Herrera MF, Kow L, Pantoja JP, Knudson MB, Tweden KS, Wilson RR, et al. VBLOC and improvements in co-morbidities in obese subjects during weight loss. Obesity Surgery. 2009;19:983–984.
    1. Tweden KS, Anvari M, Bierk MD, Billington CJ, Camilleri M, Honda CN, et al. Vagal blocking for obesity control (VBLOC): concordance of effects of very high frequency vagal blocking currents at the neural and organ levels using two pre-clinical models. Gastroenterology. 2006;130(Supplement 2):p. 148.
    1. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans. Circulation. 2005;111(5):697–716.
    1. Publication no. 03-5233. Bethesda, Md, USA: National Institutes of Health (US); 2003. The seventh report of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC-7)
    1. Bray GA, Bouchard C, Church TS, et al. Is it time to change the way we report and discuss weight loss? Obesity. 2009;17(4):619–621.
    1. Fryar CD, Carroll MD, Ogden CL. Prevalence of overweight and obesity among adults: United States, trends 1960–1962 through 2009-2010 (Health E-Stat) Hyattsville (MD): National Center for Health Statistics (US), 2012, .
    1. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968–977.
    1. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. Journal of Chronic Diseases. 1979;32(8):563–576.
    1. Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. Journal of the American Medical Association. 2008;299(3):316–323.
    1. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-En Y gastric bypass on type 2 diabetes mellitus. Annals of Surgery. 2003;238(4):467–485.
    1. Wing RR, Bahnson JL, Bray GA, et al. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the look AHEAD trial. Archives of Internal Medicine. 2010;170(17):1566–1575.
    1. Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2000;2(3):175–187.
    1. Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology. 2007;132(6):2253–2271.
    1. Scopinaro N, Papadia F, Camerini G, Marinari G, Civalleri D, Franco AG. A comparison of a personal series of biliopancreatic diversion and literature data on gastric bypass help to explain the mechanisms of resolution of type 2 diabetes by the two operations. Obesity Surgery. 2008;18(8):1035–1038.
    1. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surgery for Obesity and Related Diseases. 2007;3(6):597–601.
    1. Patriti A, Facchiano E, Sanna A, Gullà N, Donini A. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obesity Surgery. 2004;14(6):840–848.
    1. Bose M, Oliván B, Teixeira J, Pi-Sunyer FX, Laferrère B. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obesity Surgery. 2009;19(2):217–229.
    1. Bernal-Mizrachi C, Xiaozhong L, Yin L, et al. An afferent vagal nerve pathway links hepatic PPARα activation to glucocorticoid-induced insulin resistance and hypertension. Cell Metabolism. 2007;5(2):91–102.
    1. Shikora SA, Bergenstal R, Bessler M, et al. Implantable gastric stimulation for the treatment of clinically severe obesity: results of the SHAPE trial. Surgery for Obesity and Related Diseases. 2009;5(1):31–37.
    1. Dansinger ML, Tatsioni A, Wong JB, Chung M, Balk EM. Meta-analysis: the effect of dietary counseling for weight loss. Annals of Internal Medicine. 2007;147(1):41–50.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren